8:08 AM ET
8-K
M&A Deal
Benitec Biopharma M&A Deal with U.S. Food and Drug Administration
Benitec Biopharma provided a status and timeline update for its BB-301 program following a Type C meeting with the FDA. The company remains on track to initiate a pivotal study in mid-2027, with the final study design expected to be confirmed in Q1 2027 after the FDA reviews additional natural history data.
- Counterparty
- U.S. Food and Drug Administration